Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05889273Phase 2Active, not recruiting
- Sponsor
- MapLight Therapeutics
- Start
- Jun 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ML-004 in Autism Spectrum Disorder (ASD), sponsored by MapLight Therapeutics. Started Jun 2023; status: active, not recruiting.
02
Drugs
ML-004
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05889273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889273.